According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer ...

Boehringer Ingelheim reported positive growth in the first half of 2025, with group net sales growing by 6.3%* to EUR 14.0 billion.

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data ...

Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data across more than 100 ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

the white paper underscores a widespread crisis of underappreciation, operational strain and burnout, directly impacting the ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

LEO Pharma and Boehringer Ingelheim have entered into a partnership to commercialise and advance the development of ...

Boehringer Ingelheim’s outstanding workplace culture has been recognised by Top Employers Institute, a global authority that ranks excellence in people practices. Photos: Boehringer Ingelheim ...